Trending Stock News

Ocular Therapeutix, Inc. (OCUL) Analysts See $-0.58 EPS; Xenia Hotels & Resorts (XHR) SI Increased By 9.29%

Analysts expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report $-0.58 EPS on March, 9.They anticipate $0.06 EPS change or 11.54% from last quarter’s $-0.52 EPS. After having $-0.54 EPS previously, Ocular Therapeutix, Inc.’s analysts see 7.41% EPS growth. The stock decreased 0.81% or $0.04 during the last trading session, reaching $4.91. About 304,492 shares traded. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has declined 9.50% since February 19, 2017 and is downtrending. It has underperformed by 26.20% the S&P500.

Xenia Hotels & Resorts Incorporated (NYSE:XHR) had an increase of 9.29% in short interest. XHR’s SI was 3.48 million shares in February as released by FINRA. Its up 9.29% from 3.18 million shares previously. With 408,300 avg volume, 9 days are for Xenia Hotels & Resorts Incorporated (NYSE:XHR)’s short sellers to cover XHR’s short positions. The stock increased 0.05% or $0.01 during the last trading session, reaching $20.25. About 268,671 shares traded. Xenia Hotels & Resorts, Inc. (NYSE:XHR) has risen 19.57% since February 19, 2017 and is uptrending. It has outperformed by 2.87% the S&P500.

Among 8 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Ocular Therapeutix had 22 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Equal-Weight” rating given on Friday, July 14 by Morgan Stanley. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Equal Weight” rating given on Thursday, August 13 by Morgan Stanley. The stock has “Overweight” rating by Morgan Stanley on Thursday, February 18. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Outperform” rating given on Thursday, August 11 by JMP Securities. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Equal-Weight” rating by Morgan Stanley on Friday, October 23. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Buy” rating given on Wednesday, November 8 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald with “Overweight” on Wednesday, July 12. Cantor Fitzgerald initiated the stock with “Overweight” rating in Friday, February 10 report. H.C. Wainwright maintained it with “Buy” rating and $1000 target in Wednesday, August 2 report. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Outperform” rating given on Tuesday, November 15 by RBC Capital Markets.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $182.32 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The company's lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Leave a Reply

Your email address will not be published. Required fields are marked *